• No results found

Development of 18F-labeled agonist radioligands for PET imaging of the high-affinity state of cerebral dopamine D2/3 receptors

N/A
N/A
Protected

Academic year: 2021

Share "Development of 18F-labeled agonist radioligands for PET imaging of the high-affinity state of cerebral dopamine D2/3 receptors"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Development of 18F-labeled agonist radioligands for PET imaging of the high-affinity state of

cerebral dopamine D2/3 receptors

Shalgunov, Vladimir

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Shalgunov, V. (2017). Development of 18F-labeled agonist radioligands for PET imaging of the high-affinity

state of cerebral dopamine D2/3 receptors. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Propositions

Belonging to the thesis

“Development of 18F-labeled agonist radioligands for PET imaging of

the high-affinity state of cerebral dopamine D2/3 receptors”

by Vladimir Shalgunov

1. In pharmacokinetic and biodistribution studies, the advantage of the radioactive label is that it does not have to be extracted from the tissue for quantification, and the intensity and type of radioactive decay are independent of the environment (Chapter 1).

2. For G-protein coupled receptor ligands, agonism does not automatically imply preference for the “high-affinity state” of the receptors (Chapter 2).

3. Although some instances of failed attempts to detect the high-affinity state of G-protein coupled receptors in vivo may have resulted from insufficient characterization of the selectivity and intrinsic activity of the radioligands used for detection, in general these failures point to a gap in our understanding of the functioning of G-protein coupled receptors (Chapter 2).

4. The advantage of the 7-hydroxy-2-aminomethylchromane scaffold as a starting point in dopamine D2 receptor radioligand development is that it offers

convenient possibilities to accommodate the 123I or 18F label on the N-substituent, and the same substituent can also be used to adjust the lipophilicity of the candidate radioligands (Chapter 3).

5. The “stickiness” of dried [18

F]fluoride is particularly detrimental for microchannel setups, because of the high surface-to-volume ratio of the environment and the fact that drying and labelling processes take place in different locations (Chapter 6).

6. Despite great acceleration in reaction speeds, microchannel radiosynthesis systems do not provide a lot of time saving unless [18F]fluoride preparation is also miniaturized (Chapter 6).

7. New comprehensive studies that would assess the relative abundance of the high-affinity state in the same G-protein coupled receptor population using membrane homogenates, dispersed intact cells, and live animals, would shed more light on the reasons behind the current confusion regarding the existence of the high-affinity state of G-protein coupled receptors in vivo (Chapter 8).

8. Dopaminergic receptor imaging in clinical research is likely to benefit more from a novel tracer selective for dopamine D2 or D3 receptor subtypes, even if it be an

antagonist, than from a novel agonist tracer that binds indiscriminately to both named receptor subtypes (Chapter 8).

9. Research is when you do something and then find out you have done it all wrong. 10. Time spent on failures is not completely wasted if one comes to understand the

reasons behind failures.

11. Heavy buttocks are as important for a successful researcher as sharp brain. 12. Being able to integrate into and work in a team is a crucial skill if you want to be

Referenties

GERELATEERDE DOCUMENTEN

The research described in this thesis was performed at the Division of Medicinal Chemistry of the Leiden/Amsterdam Center for Drug Research, Leiden University (Leiden,

The general perception was that one overall activation mechanism should exist among class A GPCRs and that mainly the ligand binding site and the (intracellular) region that

Glycosylated or not, EL2 is thought to play a role in receptor structure, signaling, and ligand recognition, as well as ligand binding, both orthosteric and allosteric..

Next, site-saturation mutagenesis was performed on positions 71 and 74 of the A 2B R. From each of the two mutagenesis sites, 100 colonies were chosen for identification.

In a previous study, random mutagenesis combined with a yeast screen for activating mutant receptors have been performed on two parts of the adenosine A 2B receptor in order

We subsequently transformed this library in the MMY24 yeast strain and started to screen at a concentration of 1 mM 3AT, a concentration at which, as a negative control, yeast

(B) Competition binding curves with [ 3 H]DPCPX using increasing concentrations of unlabeled CPA as displacer of wild type receptor, and mutant receptors W156A and E164A in

In Chapter 4, a random mutagenesis screen of the A 2B R was described containing mutations in the fragment TM4-EL2-TM5, where mutant receptors were selected that